The Europe neurotoxins market is expected to grow from US$ 1,174.94 million in 2023 to US$ 2,038.94 million by 2028. It is estimated to register a CAGR of 11.7% from 2022 to 2028.
Based on product type, the Europe neurotoxins market is subsegmented into botox, dysport, xenomin, and others, dysport, xenomin, and others. The botox segment registered the largest market share in 2023.
Based on application, the Europe neurotoxins market is segmented into therapeutic and aesthetic. The therapeutic segment held a larger market share in 2023.
Based on end user, the market is segmented into hospitals, specialty clinics, dermatology clinics, and others. The hospitals segment held the largest market share in 2023.
Based on country, the market is segmented into the UK, Germany, France, Italy, Spain, Poland, Russia, and the Rest of Europe. Germany dominated the market share in 2023.
AbbVie Inc, Evolus Inc, Hugel Inc, Ipsen SA, Medytox Inc, and Merz Pharma GmbH & Co KGaA are among the leading companies operating in the Europe neurotoxins market.
Surge in Cosmetic Procedures to Improve Appearance Fuels Europe Neurotoxins Market
Structural changes affecting the skin, muscles, ligaments, fat, and bone get noticeable on an individual’s face due to decrease in cellular functions with aging. The inevitable physiological process of aging is generally not conceived positively by many, which, in turn, urges them to indulge in cosmetic rejuvenation procedures to remain youthful visually. Botulinum toxin (BOTA) is the most popular neurotoxin used in cosmetic procedures. The BOTA selection to treat the aforementioned case involved Abobotulinum A (ABO; Dysport/Ipsen Limited, Slough Berkshire, UK) containing 500 European units. Following the manufacturer’s recommended ratio of 2.5 ml saline solution to 500 units botulinum toxin was administered, the reconstitution was carried out. Therefore, the rising popularity of cosmetic procedures involving neurotoxins to reduce facial wrinkles while ensuring safety, effectivity, and efficiency is catalyzing the market for neurotoxins.Europe Neurotoxins Market Overview
The Europe neurotoxin market has been segmented into the UK, Germany, France, Italy, Spain, Poland, Russia, and the Rest of Europe. The surging geriatric population, rising product launches, increasing distribution of neurotoxin products, and growing government regulations for non-surgical aesthetic products and procedures will likely enhance the market growth. Also, rising numbers of aesthetic clinics may offer vital growth opportunities for market growth. In the UK, there was no industry to regulate the standards for non-surgical procedures. Also, there was no need for a legal license to perform Botox or filler injections procedures. Thus, these were the leading factors that defined the growth of the neurotoxin market in the past few years across the country. However, in 2013, Health Education England developed standards and qualifications frameworks for practitioners' failings to improve public protection and to reduce risks that may cause severe side effects of aesthetic procedures.Exhibit: Europe Neurotoxins Market Revenue and Forecast to 2028 (US$ Million)
Europe Neurotoxins Market Segmentation
The Europe neurotoxins market is segmented into product type, application, end user, and country.Based on product type, the Europe neurotoxins market is subsegmented into botox, dysport, xenomin, and others, dysport, xenomin, and others. The botox segment registered the largest market share in 2023.
Based on application, the Europe neurotoxins market is segmented into therapeutic and aesthetic. The therapeutic segment held a larger market share in 2023.
Based on end user, the market is segmented into hospitals, specialty clinics, dermatology clinics, and others. The hospitals segment held the largest market share in 2023.
Based on country, the market is segmented into the UK, Germany, France, Italy, Spain, Poland, Russia, and the Rest of Europe. Germany dominated the market share in 2023.
AbbVie Inc, Evolus Inc, Hugel Inc, Ipsen SA, Medytox Inc, and Merz Pharma GmbH & Co KGaA are among the leading companies operating in the Europe neurotoxins market.
Table of Contents
1. Introduction
3. Research Methodology
4. Europe Neurotoxin Market - Market Landscape
5. Europe Neurotoxin Market - Key Market Dynamics
6. Europe Neurotoxin Market
7. Europe Neurotoxin Market - Revenue and Forecast to 2028 - By Type
8. Europe Neurotoxin Market - Revenue and Forecast to 2028 - By Application
9. Europe Neurotoxin Market - Revenue and Forecast to 2028 - By End User
10. Europe Neurotoxin Market -Revenue and Forecast to 2028- Country Analysis
11. Europe Neurotoxins Market-Industry Landscape
12. Company Profiles
13. Appendix
List of Tables
List of Figure
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc
- Evolus Inc
- Hugel Inc
- Ipsen SA
- Medytox Inc
- Merz Pharma GmbH & Co KGaA
